Impact of FDA black box advisory on antipsychotic medication use

E. Ray Dorsey, Atonu Rabbani, Sarah A. Gallagher, Rena M. Conti, George Caleb Alexander

Research output: Contribution to journalArticle

Abstract

Background: In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown. Methods:Weused quasi-experimental, interrupted timeseries analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia. Results: From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia. In 2004, 19% (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9% (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined. Conclusion: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.

Original languageEnglish (US)
Pages (from-to)96-103
Number of pages8
JournalArchives of Internal Medicine
Volume170
Issue number1
DOIs
StatePublished - Jan 11 2010
Externally publishedYes

Fingerprint

United States Food and Drug Administration
Antipsychotic Agents
Dementia
Pharmaceutical Preparations
Drug Labeling
Physicians' Offices
Health
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Impact of FDA black box advisory on antipsychotic medication use. / Dorsey, E. Ray; Rabbani, Atonu; Gallagher, Sarah A.; Conti, Rena M.; Alexander, George Caleb.

In: Archives of Internal Medicine, Vol. 170, No. 1, 11.01.2010, p. 96-103.

Research output: Contribution to journalArticle

Dorsey, E. Ray ; Rabbani, Atonu ; Gallagher, Sarah A. ; Conti, Rena M. ; Alexander, George Caleb. / Impact of FDA black box advisory on antipsychotic medication use. In: Archives of Internal Medicine. 2010 ; Vol. 170, No. 1. pp. 96-103.
@article{3101dce8c5fc435998abf954a2c45fa2,
title = "Impact of FDA black box advisory on antipsychotic medication use",
abstract = "Background: In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown. Methods:Weused quasi-experimental, interrupted timeseries analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia. Results: From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34{\%}, and among patients with dementia, 16{\%}. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2{\%} overall and 19{\%} among those with dementia. In 2004, 19{\%} (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9{\%} (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined. Conclusion: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.",
author = "Dorsey, {E. Ray} and Atonu Rabbani and Gallagher, {Sarah A.} and Conti, {Rena M.} and Alexander, {George Caleb}",
year = "2010",
month = "1",
day = "11",
doi = "10.1001/archinternmed.2009.456",
language = "English (US)",
volume = "170",
pages = "96--103",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Impact of FDA black box advisory on antipsychotic medication use

AU - Dorsey, E. Ray

AU - Rabbani, Atonu

AU - Gallagher, Sarah A.

AU - Conti, Rena M.

AU - Alexander, George Caleb

PY - 2010/1/11

Y1 - 2010/1/11

N2 - Background: In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown. Methods:Weused quasi-experimental, interrupted timeseries analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia. Results: From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia. In 2004, 19% (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9% (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined. Conclusion: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.

AB - Background: In April 2005, the US Food and Drug Administration (FDA) issued an advisory and subsequent black box warning regarding the risks of atypical antipsychotic use among elderly patients with dementia. The impact of these warnings on atypical drug use is unknown. Methods:Weused quasi-experimental, interrupted timeseries analyses to examine nationally representative data from IMS Health's National Disease and Therapeutic Index from January 2003 through December 2008. The primary measurement from this audit of office-based physicians was the use of an atypical antipsychotic agent. We quantified the impact of the advisory on atypical antipsychotic use among all individuals and those 65 years or older with dementia. Results: From January 2003 to March 2005, mentions of total atypical antipsychotic drugs increased at an annual rate of 34%, and among patients with dementia, 16%. In the year prior to the FDA advisory, there were approximately 13.6 million atypical drug mentions, including 0.8 million among those with dementia. In the year following the advisory, atypical drug mentions fell 2% overall and 19% among those with dementia. In 2004, 19% (0.8 of 4.1 million) of drug mentions for dementia were for an atypical agent. By 2008, this proportion decreased to 9% (0.4 of 4.3 million). Atypical drug use slowed for both FDA-approved and off-label indications and declined through 2008 for all populations examined. Conclusion: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.

UR - http://www.scopus.com/inward/record.url?scp=74549137304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549137304&partnerID=8YFLogxK

U2 - 10.1001/archinternmed.2009.456

DO - 10.1001/archinternmed.2009.456

M3 - Article

C2 - 20065205

AN - SCOPUS:74549137304

VL - 170

SP - 96

EP - 103

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 1

ER -